Stocks of companies including Paytm, BSE, Indian Hotels, Paras Defence, Rategain, and Coforge are in focus for Tuesday's trading session following recent corporate developments and earnings announcements. The stock market began the week with modest gains, up 0.5%, as it continues its consolidation phase.

Earnings Watch: Paytm, BSE, and Bank of Baroda are set to announce their Q4 FY25 earnings.

Indian Hotels: The Indian Hotels Company (IHCL) reported a consolidated net profit of Rs 522 crore for Q4FY25, a 25% year-over-year (YoY) increase compared to Rs 418 crore in the previous year.

Indian Energy Exchange (IEX): In April, IEX recorded a total traded volume of 10,584 million units (MU), a 26% YoY growth. The Day-Ahead Market (DAM) contributed 4,231 MU, up 3%, while the Real-Time Market (RTM) surged 48% YoY to 3,893 MU. The average price in DAM was Rs 5.20 per unit for the month.

Paras Defence: Paras Defence signed a Memorandum of Understanding (MoU) with Israel-based HevenDrones to expand their presence in Indian and global defence markets. The joint venture aims to develop and manufacture logistics and cargo drones for defence and civilian applications.

Ircon International: Ircon International secured a work order worth Rs 187.08 crore from Kerala State IT Infrastructure for developing a Dedicated Rural Industrial Park in Thiruvananthapuram.

Rategain Travel Technologies: Rategain announced leadership changes, appointing Deepak Kapoor as the new Chief Technology Officer (CTO) and Rohan Mittal as the Chief Financial Officer (CFO).

Fortis Healthcare: Fortis Hospitals, a subsidiary of Fortis Healthcare, received a rectification order under the Income Tax Act, reducing a previous tax demand of Rs 89.53 crore for Assessment Year 2022–23 to zero.

Coforge: Coforge reported a consolidated net profit of Rs 261.2 crore for the March quarter. However, its rupee revenue was lower than estimates, coming in at Rs 3,409.9 crore compared to the projected Rs 3,530 crore.

Glenmark Pharma: Glenmark Pharmaceuticals' innovation arm, Ichnos Glenmark Innovation (IGI), received ‘fast track’ status from the US FDA for its investigational multiple myeloma therapy, ISB 2001.